What is he best known for?
The fields of study he is best known for:
- Antibody
- Gene
- Immune system
Richard M. Scearce spends much of his time researching Virology, Antibody, Epitope, Molecular biology and Monoclonal antibody.
The study incorporates disciplines such as Immunogen, Immunology and Immunogenicity in addition to Virology.
He has researched Antibody in several fields, including Immune system, Glycoprotein and Vaccination.
His Vaccination research incorporates themes from Mutation and Neutralization.
His Epitope study frequently involves adjacent topics like Virus.
His Neutralizing antibody study combines topics from a wide range of disciplines, such as T cell, B cell and Antigen.
His most cited work include:
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (776 citations)
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (776 citations)
- Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies (651 citations)
What are the main themes of his work throughout his whole career to date?
Richard M. Scearce mostly deals with Antibody, Virology, Molecular biology, Monoclonal antibody and Epitope.
Richard M. Scearce has included themes like T cell, Antigen and Vaccination in his Antibody study.
Richard M. Scearce mostly deals with Virus in his studies of Virology.
His Molecular biology research is multidisciplinary, incorporating perspectives in Receptor, breakpoint cluster region, Ligand, Protein structure and Naive B cell.
His Monoclonal antibody research integrates issues from Epithelium, Western blot, Cellular differentiation and Glycoprotein.
His study explores the link between Epitope and topics such as Peptide sequence that cross with problems in Amino acid.
He most often published in these fields:
- Antibody (71.58%)
- Virology (62.11%)
- Molecular biology (43.16%)
What were the highlights of his more recent work (between 2016-2021)?
- Antibody (71.58%)
- Virology (62.11%)
- Immunization (11.58%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Antibody, Virology, Immunization, Vaccination and Recombinant DNA.
The Antibody study combines topics in areas such as Molecular biology, Naive B cell and Immune system.
His Virology research is multidisciplinary, relying on both Immunology, Glycan, Epitope and Immunogen, Monoclonal antibody.
The various areas that Richard M. Scearce examines in his Epitope study include Immunoglobulin heavy chain, Glutamic acid and Aspartic acid.
He studied Vaccination and HIV vaccine that intersect with Viremia, Immunogenicity, Vaccine trial and Simian immunodeficiency virus.
His Neutralizing antibody research is multidisciplinary, incorporating elements of Antigen and Affinity maturation.
Between 2016 and 2021, his most popular works were:
- Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination (367 citations)
- Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. (113 citations)
- Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge (79 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Antibody
- Immune system
Antibody, Virology, Immunization, Vaccination and Immunogen are his primary areas of study.
His Antibody research includes elements of Molecular biology, Binding site and Antigen.
The Molecular biology study combines topics in areas such as T cell, Immune system, Affinity maturation and Germinal center, B cell.
His studies in Binding site integrate themes in fields like HIV vaccine and Heterologous.
His work on Viral Vaccine as part of general Vaccination study is frequently linked to Pandemic, bridging the gap between disciplines.
His Immunogen research incorporates themes from Recombinant DNA, Pentavalent vaccine, Antibody-dependent cell-mediated cytotoxicity, Vaccine efficacy and Serology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
